

University of Groningen

C/EBP β isoforms and the regulation of metabolism

Ackermann, Tobias

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Ackermann, T. (2018). *C/EBP β isoforms and the regulation of metabolism: A fine balance between health and disease*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Scientific summary

The regulation of metabolism has direct impact on the health of an organism and the proliferation and survival capacities of cells. Therefore, a deregulated metabolism results in the development of diseases at the organismal (e.g. diabetes) and cellular (e.g. cancer) level. Many proteins involved in the regulation of metabolism are tumour suppressors or oncogenes. It is shown that a heterogeneous deletion (e.g. *IGF1R*, *MYC*) or pharmacological inhibition (mTORC1 by rapamycin) of some proto-oncogenes leads to a lifespan extension and healthy metabolism in mammals.

In this thesis, we describe that C/EBP β -LIP translation is controlled by mTORC1 signalling. Deficiency in C/EBP β -LIP translation causes healthy metabolism in mice, which resembles the phenotype of other mouse models with reduced mTORC1 signalling or protein translation. Further, we show that C/EBP β -LIP is able to reduce fatty acid oxidation and increase glucose metabolism and energy level in the cell. We identified the let-7 family of tumour suppressive microRNAs as novel C/EBP β targets and the let-7 target and stem cell factor LIN28B as an important mediator of LIP induced metabolic reprogramming. Furthermore, LIP reprograms the cytoplasmic NADH utilisation by stimulating the malate-aspartate-shuttle and the usage of electrons from cytoplasmic NADH in OXPHOS and thereby possibly increases *de novo* biosynthesis from glucose. Moreover, we show that high LIP level impose a metabolic vulnerability on cells. Glucose starvation or inhibition of glycolysis causes low NADH level and thereby leads to apoptosis specifically in cells with high LIP level.

Our data suggests C/EBP β -LIP as an important mediator of metabolic signalling since its expression is responsive to nutrient levels (through mTORC1) and it controls cellular metabolism (through let-7/LIN28B). Therefore, we suggest a nutrient level based negative feedback loop for LIP expression in the cell. Furthermore, we speculate that a loss of this feedback loop results in activation of apoptosis under nutrient limiting conditions, which should be exploited for future therapeutic strategies for cancer types that are characterized by high LIP levels.